TRV GP IV’s Dianthus Therapeutics DNTH Stock Holding History

TRV GP IV’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-422,388	Closed	-$2.67M	–	4
2022 Q4	$2.67M	Hold	422,388	–	–	1.14%	5
2022 Q3	$9.53M	Hold	422,388	–	–	5.57%	5
2022 Q2	$8.11M	Hold	422,388	–	–	5.33%	5
2022 Q1	$19.6M	Hold	422,388	–	–	7.18%	4
2021 Q4	$29.9M	Hold	422,388	–	–	8.61%	4
2021 Q3	$49.2M	Sell	422,388 -78,125	-16%	-$9.1M	11.16%	3
2021 Q2	$78.3M	Hold	500,513	–	–	37.29%	1
2021 Q1	$94.8M	Hold	500,513	–	–	34.93%	1
2020 Q4	$62.8M	Hold	500,513	–	–	20.14%	2
2020 Q3	$54.5M	Hold	500,513	–	–	18.75%	2
2020 Q2	$60.1M	Hold	500,513	–	–	27.71%	2
2020 Q1	$50.3M	Hold	500,513	–	–	45.98%	1
2019 Q4	$121M	Hold	500,513	–	–	75.69%	1
2019 Q3	$82.2M	Hold	500,513	–	–	84.08%	1
2019 Q2	$118M	Hold	500,513	–	–	100%	1
2019 Q1	$132M	Hold	500,513	–	–	100%	1
2018 Q4	$45.6M	Buy	+500,513	New	+$68.2M	100%	1

Other funds holding DNTH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return

TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

TRV GP IV's DNTH Position: Q1 2023 in Review

TRV GP IV sold out of Dianthus Therapeutics (DNTH) in Q1 2023, closing a stake of 422,388 shares — an estimated $2.67M sold.

TRV GP IV first reported a position in DNTH in Q4 2018 and held it in 17 quarters. The position peaked at $132M in Q1 2019. 52 funds tracked by Wall St. Rank hold DNTH as of Q1 2023.

TRV GP IV reported no remaining Dianthus Therapeutics position as of Q1 2023 after selling out during the quarter.
TRV GP IV sold 422,388 Dianthus Therapeutics shares in Q1 2023, an estimated $2.67M.
TRV GP IV first reported a position in Dianthus Therapeutics in Q4 2018 and held it in 17 quarters.
TRV GP IV's Dianthus Therapeutics position peaked at $132M in Q1 2019.
52 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2023.

Based on TRV GP IV's 13F filing for Q1 2023, filed 12 May 2023.